Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,424 across all filing types
Latest filing 2025-05-20 Investor Presentation
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Press Release Q4 FY25
Investor Presentation Classification · 95% confidence The document is a press release and investor presentation dated May 20-21, 2025, announcing audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2025. It includes detailed financial highlights, business performance commentary, and an invitation to an earnings call. The content includes comprehensive financial data and analysis for Q4 FY25 and FY25, along with strategic commentary from the Managing Director. The document is about quarterly and annual financial results but is not a full annual report (10-K) or an interim report alone; it is primarily a press release combined with an investor presentation. The presence of detailed financial results and the investor presentation aligns best with an Earnings Release (ER) and Investor Presentation (IP). However, since the document includes both the press release announcing the earnings and the investor presentation, the classification should be Investor Presentation (IP) as it is the more detailed and comprehensive document type covering financials, strategy, and market position. The document is 15,000 characters long, indicating it is a full presentation rather than a brief announcement or regulatory filing. Therefore, the best fit is Investor Presentation (IP).
2025-05-20 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a press release and investor presentation dated May 20-21, 2025, announcing the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2025. It includes detailed financial highlights, business performance commentary, and an invitation to an earnings call. The content is focused on financial results and company performance, typical of an Earnings Release combined with an Investor Presentation. The document is about 15,000 characters long, which is consistent with a detailed investor presentation and press release, not a full annual report or interim report. The presence of an earnings call announcement and detailed financial metrics supports classification as an Earnings Release (ER) and Investor Presentation (IP). Since the document includes both a press release and a detailed investor presentation, the best fitting category is Investor Presentation (IP), which covers detailed presentations for investors focusing on financials, strategy, and market position. The press release announcing earnings is part of the presentation package. Therefore, the filing type code is IP with high confidence.
2025-05-20 English
Press Release
Investor Presentation Classification · 95% confidence The document is a press release and investor presentation dated May 20-21, 2025, announcing the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2025. It includes detailed financial highlights, business performance commentary, and an invitation to an earnings call. The content is typical of an Earnings Release combined with an Investor Presentation. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis, not just a brief announcement or a link to a report. The presence of detailed slides and financial metrics confirms it is an Investor Presentation. The initial part is a press release announcing the earnings results, which fits the Earnings Release category. Since the document contains both the earnings announcement and the detailed investor presentation, the best classification is Investor Presentation (IP), as it encompasses the detailed financial and strategic information provided. The press release portion is part of the presentation package. Therefore, the filing type code is IP with high confidence.
2025-05-20 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Sequent Scientific Limited dated May 20, 2025. It reports the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The document includes detailed financial statements such as the statement of audited standalone financial results, balance sheet, and notes. It also mentions the auditor's report with an unmodified opinion, which is enclosed. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis, not just a notification or summary. This matches the characteristics of an Annual Report or a comprehensive financial report covering a full fiscal year. However, since it is specifically the audited financial results for the year ended March 31, 2025, and includes both standalone and consolidated results, it aligns best with the Annual Report (10-K) category, which covers the official yearly report with full financial performance. Therefore, the document should be classified as 10-K with high confidence.
2025-05-20 English
Alivira Animal Health Limited ("AAHL"), a wholly owned subsidiary of the Company, has agreed for a one -time settlement of the disputes in relation to its leasehold land situated at Visakhapatnam.
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) referencing Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about a one-time settlement of disputes related to leasehold land by a wholly owned subsidiary. The document includes details required under SEBI regulations and a settlement amount, but it does not contain financial statements or detailed financial analysis. The length is 3913 characters, which is relatively short and the document serves as an announcement of a material event or update rather than a full report. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement about a material event under SEBI Listing Regulations, not a full financial report or earnings release.
2025-05-20 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) referencing Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It discloses a one-time settlement of disputes related to leasehold land by a wholly owned subsidiary. The document includes details required under SEBI regulations and a summary of the settlement amount and its impact on financial results. There are no financial statements or detailed financial analysis present, and the document is relatively short (3913 characters). It is an announcement of a material event or update as required by regulatory disclosure norms, not a full financial report or earnings release. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.